Diabetic Ketoacidosis (DKA) in Dogs — Management Guide

Concise, practical guide to recognizing and managing diabetic ketoacidosis (DKA) in dogs — emergency presentation, ICU care (fluids, insulin CRI, electrolytes), transition to maintenance insulin, and prevention.

Quick Overview

• What it is: Diabetic ketoacidosis (DKA) is a life‑threatening complication of diabetes mellitus characterized by insulin deficiency, hyperglycemia, metabolic acidosis, and accumulation of ketone bodies (β‑hydroxybutyrate, acetoacetate). It requires emergency veterinary care and ICU management.
• Who’s at risk: Dogs with previously undiagnosed diabetes, poorly controlled diabetics (inconsistent insulin/feeding), or those with concurrent illnesses (infection, pancreatitis, hyperadrenocorticism, corticosteroid therapy). Certain breeds (see below) are predisposed to diabetes.
• Prognosis: Variable depending on severity and comorbidities. With prompt ICU treatment, many dogs survive to discharge; reported in‑hospital survival often ranges from ~60–85% depending on study/population and available care. Long‑term outcome depends on owner compliance and control of underlying disease.

Pathophysiology — explained simply

Insulin deficiency (absolute or relative) prevents glucose from entering cells. The body responds by breaking down fat and protein for energy. Fat breakdown produces free fatty acids that the liver converts to ketone bodies. Excess ketones are acidic, causing metabolic acidosis. High blood glucose causes osmotic diuresis, dehydration, and loss of electrolytes (potassium, sodium, chloride, phosphate). Dehydration and acidosis impair perfusion and organ function, aggravating the problem.

Breed-specific risk factors and prevalence

• Diabetes mellitus in dogs is most commonly insulin‑dependent (Type 1–like). Certain breeds have higher risk: Samoyeds, Miniature Schnauzers, Poodles (Toy and Mini), Dachshunds, Australian Terriers, West Highland White Terriers, Keeshonds.
• Middle‑aged to older spayed females are overrepresented in many populations.
• Prevalence of DKA among diabetic dogs varies. Many newly diagnosed diabetics present with DKA; others develop it during poor control or secondary illness.

Common signs (often acute to subacute, hours to days):

• Polyuria/polydipsia (PU/PD), weight loss
• Vomiting, anorexia, lethargy, weakness
• Dehydration, tachycardia, hypotension
• Tachypnea (Kussmaul-like), acetone/fruit odor on breath
• Neurologic signs (depression, obtundation, seizures) in severe cases

• Mild DKA: moderate hyperglycemia, low‑level ketosis, mild dehydration, pH >7.2
• Moderate DKA: marked hyperglycemia and ketonuria/ketonemia, dehydration 6–10%, pH 7.0–7.2
• Severe DKA: severe dehydration (>10%), pH <7.0–7.1, altered mentation, evidence of shock or organ failure

Initial assessment

• Rapid triage: cardiovascular status, airway, breathing. Begin stabilization — oxygen and IV access if needed.
• Point‑of‑care glucose: hyperglycemia is expected; however, euglycemic DKA is possible (rare).

• Serum biochemistry (glucose, electrolytes, BUN/creatinine, liver enzymes, total bilirubin)
• Venous blood gas (pH, bicarbonate) and lactate
• Serum ketone measurement (blood β‑hydroxybutyrate preferred) and/or urine ketones
• Complete blood count (CBC) — look for infection/inflammation
• Urinalysis and urine culture (suspected UTI)
• Electrocardiogram (if marked potassium abnormalities suspected)
• Imaging as indicated: thoracic rads or abdominal ultrasound to identify concurrent disease (pneumonia, pancreatitis, pyelonephritis, etc.)

• Blood glucose every 1–2 hours while on insulin CRI (or until stable)
• Electrolytes (K+, Na+, Cl−), blood gas, and hematocrit every 4–6 hours initially
• Monitor urine output, body temperature, and neurologic status

• Consider referral to an emergency/critical care hospital or internal medicine specialist if severe hypotension, refractory acidosis, need for mechanical ventilation, persistent hyperglycemia despite therapy, or complex comorbidities.

Goals: Restore perfusion and hydration, correct metabolic derangements, suppress ketogenesis with insulin, identify and treat triggers.

1) Initial fluid resuscitation

• Crystalloids are first line (isotonic balanced solutions such as Lactated Ringer’s Solution or Plasma‑Lyte).
• Shocky/hypotensive dogs: bolus 10–20 mL/kg IV over 15–30 minutes, reassess. Repeat as needed guided by perfusion.
• After initial resuscitation, calculate ongoing deficit and maintenance; rehydrate over 12–24 hours initially depending on cardiovascular status. Typical total replacement in first 24 hours often aims to correct deficit + maintenance + ongoing losses.
• Avoid abrupt large volumes in cardiac disease; titrate carefully.

• Regular (short‑acting) insulin is used IV as a continuous rate infusion (CRI) in the ICU.
• Common practical protocols (two widely used approaches):

• Target: gradual BG reduction of ~50–100 mg/dL per hour (2.8–5.6 mmol/L/h), avoiding rapid drops that risk cerebral edema or hypoglycemia.
• Once BG reaches ~200–250 mg/dL (11–14 mmol/L), add dextrose to maintenance fluids (5%–10% dextrose) and reduce insulin infusion rate to prevent hypoglycemia while continuing to clear ketones. Continue insulin until ketonemia/ketonuria and anion gap have normalized and the patient is eating and clinically improving.

• Potassium shifts out of blood early in DKA — total body potassium is low. Insulin therapy shifts potassium intracellularly and can precipitate hypokalemia.
• Begin potassium supplementation once urine output is adequate and initial K+ level is known. Typical additions: 20–40 mEq KCl per liter of crystalloid is common; total rate often targeted to deliver approximately 0.5–1.0 mEq/kg/hour depending on initial serum K+ and serial measurements.
• Target serum K+: ~3.5–5.5 mmol/L. If K+ <3.0 mmol/L, pause insulin CRI and aggressively replace potassium until safer levels are reached.

• Phosphate may be depleted; clinical hypophosphatemia (<1.0 mg/dL or <0.3 mmol/L) can cause muscle weakness, hemolysis. Replace if severe or symptomatic. A typical phosphate supplement: potassium phosphate (KPhos) — doses individualized (e.g., 0.1–0.5 mmol/kg over several hours), monitoring calcium and potassium.
• Magnesium replacement may be needed if low; typical protocols replace magnesium sulfate 0.1–0.5 mEq/kg IV slowly.

• Metabolic acidosis usually corrects with fluids and insulin. Sodium bicarbonate therapy is rarely indicated and may be harmful; consider only if pH <7.0–7.1 with hemodynamic instability and after consultation with a specialist.

• Search for and treat precipitating factors: infections (UTI, pneumonia, pyelonephritis), pancreatitis, dental disease, steroid administration, other endocrine disease.
• Start appropriate antimicrobials guided by culture when infection suspected.

Criteria for transition

• Patient is eating or can be fed reliably
• Ketones have resolved or are minimal (blood β‑hydroxybutyrate reduced)
• Anion gap normalized and pH near normal
• Stable hydration, electrolytes, and glucose trend without frequent hypoglycemia

• Stop insulin CRI and allow a short bridge period before giving first subcutaneous (SC) dose; many clinicians give the first SC dose 1–2 hours after stopping the infusion to avoid overlap and hypoglycemia.
• Choose an appropriate intermediate/long‑acting insulin for home use. Options commonly used in dogs: lente insulins (Vetsulin/Caninsulin — porcine lente), NPH (human recombinant) or basal insulin analogs depending on clinician preference and local availability.
• Starting outpatient dose commonly ranges 0.25–0.5 U/kg SC every 12 hours, individualized. Many dogs are started on ~0.25–0.5 U/kg q12h and doses adjusted based on home glucose monitoring.
• Continue close inpatient monitoring for 12–24+ hours after transition to SC insulin to ensure stability.

• Frequent blood glucose checks: curve or spot checks (pre‑prandial and several times post‑prandial) in the first 1–2 weeks. Consider continuous glucose monitoring (CGM) if available.
• Recheck electrolytes, renal values, and fructosamine in 7–14 days and as needed.
• Adjust dose based on glucose curves and clinical signs. Work with your veterinarian or veterinary internist.

• Consistent routine: fixed feeding times and insulin administration schedule (most dogs respond well to q12h dosing tied to meals).
• Correct insulin type and dose titrated to glucose monitoring; educate owners on injection technique and hypoglycemia recognition.
• Treat and prevent concurrent illness: dental care, vaccination, parasite control, early treatment of infections. Monitor for pancreatitis and adrenal disease.
• Regular vet checks: weight monitoring, body condition scoring, periodic glucose curves, fructosamine every 2–3 months initially, then spaced out when stable.
• Owner education: signs of hypoglycemia (weakness, tremors, collapse) and hyperglycemia/DKA (anorexia, vomiting, rapid breathing), how to check urine glucose and ketones at home if advised.

• Short‑term prognosis depends on severity, speed of treatment, and comorbidities. With proper ICU care many dogs recover and go on to a good quality of life as controlled diabetics.
• Long‑term prognosis depends on owner compliance with insulin, feeding routine, and monitoring, and on whether underlying triggers are controlled.
• Many dogs live months to years with good control; some require frequent adjustments. Discuss realistic expectations with your veterinarian.

• Establish a consistent routine: same food, feeding times, and insulin schedule every day.
• Use a calendar or app to record insulin doses, appetite, water intake, vomiting, and glucose/urine test results.
• Always carry a source of fast glucose (glucose gel, syrup, liquid sugar) and know how to administer it for hypoglycemia. Seek immediate vet care for severe signs.
• Keep scheduled rechecks and bloodwork; request veterinary instruction for home BG monitoring or CGM use.
• Avoid abrupt diet changes; discuss treats and weight management with your clinician.

Seek immediate veterinary care (emergency) if your dog has any of the following:

• Persistent vomiting or inability to eat for >24 hours
• Rapid or difficult breathing or collapse
• Marked weakness, severe lethargy, or seizures
• Sudden inability to stand, collapse, or stupor
• Repeatedly positive urine ketones at home or blood β‑hydroxybutyrate elevated
• Severe hypoglycemic episode (seizure, unconsciousness)

• Regular insulin CRI: 0.05–0.1 U/kg/hour IV (some protocols use 0.1 U/kg IV bolus then 0.1 U/kg/hr CRI; many clinicians prefer starting CRI without bolus to lower hypoglycemia risk).
• Fluid bolus: 10–20 mL/kg isotonic crystalloid for initial resuscitation; reassess frequently.
• Potassium supplementation: commonly add 20–40 mEq/L KCl to fluids; target K+ ~3.5–5.5 mmol/L. Replace cautiously and monitor electrolytes frequently.
• Dextrose addition: begin 5–10% dextrose when blood glucose approaches 200–250 mg/dL to allow continued insulin action without hypoglycemia.

• Several retrospective studies and reviews report in‑hospital survival rates commonly in the 60–85% range, with worse outcomes associated with severe acidemia, comorbid organ dysfunction, and advanced age. Outcomes vary by hospital resources and timeliness of care. (See Merck Veterinary Manual and specialty literature for study details.)

• Merck Veterinary Manual — Diabetic Ketoacidosis: https://www.merckvetmanual.com/endocrine-system/diabetes-mellitus/diabetic-ketoacidosis
• Veterinary internal medicine textbooks and ACVIM resources on diabetes mellitus and DKA (consult your veterinarian for guideline updates).

Frequently Asked Questions